| Ytd | 45.48% | |
| 1y | -39.34% |
| Open | 1.15 | Prev Close | 1.15 | Low | 1.11 | High | 1.15 | Mkt Cap | 8.96M |
| Vol | 21.94K | Avg Vol | 41.90K | EPS | -0.37 | P/E | N/A | Forward P/E | -198.54 |
| Beta | 1.17 | Short Ratio | 1.18 | Inst. Own | 0.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 1.13 | 200-d Avg | 1.03 | 1yr Est | 4.69 |
IMRN News
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) a
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media p
MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an
Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consultin
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeki
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Fla
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pc
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released
Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the sam
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a F
Sales Highlights (unaudited):GlobalH1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp
As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed A
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigati
IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protoco
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced t
Sales Highlights (unaudited):Global• Q1 sales AUD$2.0 million up 34% on prior comparative period (pc
Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (
Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical developmen
US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs o
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceuti
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) adv
GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on p
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Qua
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services U
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highe
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on p
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session af